Acrux terminates Napa licence
08 November, 2005 by Ruth BeranAcrux DDS, a wholly owned subsidiary of Melbourne-based Acrux (ASX:ACR), has terminated an exclusive licence agreement it signed in May 2005 with US firm Napa Biosciences.
CyGenics acquires 51 per cent of BioCell
08 November, 2005 by Ruth BeranCell therapy company CyGenics (ASX:CYN) has taken a 51 per cent controlling equity interest in cord blood stem cell banking business BioCell.
Cytopia picks up $3m grant
08 November, 2005 by Graeme O'NeillMelbourne oncology drug developer Cytopia (ASX:CYT) has been offered a AUD$3 million federal government Commercial Ready grant to expand clinical development of its lead anti-cancer drug CYT997.
Panbio names new CEO
04 November, 2005 by Helen SchullerBrisbane medical diagnostics developer Panbio (ASX:PBO) has successfully completed a seven-month search for a new CEO in what executive chairman Jim Kalokerinos has described as a "longer process than hoped."
GTG, Applera look to be nearing settlement
04 November, 2005 by Graeme O'NeillMelbourne-based gene testing company Genetic Technologies (ASX:GTG, NASDAQ:GENE) appears to be nearing settlement of its long-running court case against US rival Applera Corp over Applera's refusal to take a licence to use GTG's patents on the use of so-called 'junk' DNA markers for gene testing.
Regenera eyes merger with US firm, CEO resigns
04 November, 2005 by Helen SchullerPerth-based Regenera (ASX:RGA) has revealed plans to acquire US-based Advanced Ocular Systems (AOS) for US$31 million (AUD$40 million) in a plan to expand its portfolio of ophthalmic products and technologies.
Alchemia raises $14.6m, aims to add another $5m
03 November, 2005 by Ruth BeranAlchemia (ASX:ACL) has raised AUD$14.6 million through a share placement and will commence a share purchase plan (SPP) to offer an additional $5 million to existing shareholders.
Bionomics licenses two epilepsy diagnostics to LabCorp
03 November, 2005 by Helen SchullerBionomics (ASX:BNO) has licensed two genetic tests for the diagnosis of epilepsy to US giant Laboratory Corporation of America.
Chemeq's loan terms changed to include revenues, assets
03 November, 2005 by Ruth BeranPerth-based antimicrobial specialist Chemeq (ASX:CMQ) has agreed to vary the terms of the AUD$60 million convertible bonds issued to the company earlier this year, requiring the company to make revenues of at least $4 million in 2005-06 and to have liquid assets of $24 million or more.
Adipogen raises $2.25m for obesity drug, CEO
02 November, 2005 by Helen SchullerUnlisted Brisbane-based company Adipogen has raised a further AUD$2.25 million to support the development of a novel treatment for obesity.
German biotech firm Jerini's shares fall on IPO debut
02 November, 2005 by Staff WritersShares in German biotech firm Jerini fell as much as 6 per cent in their debut on Tuesday amid what traders said was a worsening climate for new listings in Frankfurt and scepticism about biotech offers.
Qld team develops burns therapy device
01 November, 2005 by Helen SchullerA team of Queensland researchers has developed a technology that reduces anxiety and distress during the treatment of burns and may act as a supplement for the use of sedatives for young children.
Cloning rescues rare cattle breed
01 November, 2005 by Graeme O'NeillJust over seven years ago, in August 1998, Dr David Wells of the Ruakua Research Centre in Hamilton announced the successful cloning of the last Enderby Island Cow, the last survivor of a the world's rarest cattle breed.
Thoroughbred specialist to raise up to $4.25 million in backdoor listing
01 November, 2005 by Helen SchullerSouth Australian-based Vet Biotechnology (NSX:VBL) is aiming to raise up to AUD$4.25 million in capital to fund development of a vaccine against 'rattles' disease in racehorses by a backdoor listing on the ASX in late November through Plantcorp.
pSivida commences phase IIb clinical trials
31 October, 2005 by Helen SchullerPerth-based bio-nanotech company pSivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has commenced its phase IIb clinical trials with its BrachySil technology as a potential treatment for inoperable primary liver cancer.
